TRCT
INMB icon

Tower Research Capital (TRC)’s INmune Bio INMB Stock Holding History

Tower Research Capital (TRC)’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.3K Buy
11,772
+5,860
+99% +$8.35K ﹤0.01% 3752
2025
Q4 		$9.22K Sell
5,912
-692
-10% -$1.24K ﹤0.01% 3913
2025
Q3 		$13.7K Buy
6,604
+4,303
+187% +$9.85K ﹤0.01% 3664
2025
Q2 		$5.32K Buy
2,301
+279
+14% +$2.05K ﹤0.01% 4206
2025
Q1 		$15.8K Sell
2,022
-152
-7% -$1.21K ﹤0.01% 3203
2024
Q4 		$10.2K Sell
2,174
-908
-29% -$4.73K ﹤0.01% 3835
2024
Q3 		$16.6K Buy
+3,082
New +$21.9K ﹤0.01% 3354
2024
Q2 		– Sell
-2,255
Closed -$26.5K – 5839
2024
Q1 		$26.5K Buy
2,255
+721
+47% +$8.71K ﹤0.01% 2754
2023
Q4 		$17.3K Sell
1,534
-1,009
-40% -$8.46K ﹤0.01% 3745
2023
Q3 		$17.2K Buy
2,543
+973
+62% +$8.07K ﹤0.01% 3515
2023
Q2 		$14.3K Sell
1,570
-467
-23% -$3.75K ﹤0.01% 3712
2023
Q1 		$13K Buy
2,037
+534
+36% +$4.3K ﹤0.01% 3976
2022
Q4 		$10K Sell
1,503
-2,406
-62% -$17.1K ﹤0.01% 4016
2022
Q3 		$25K Buy
+3,909
New +$34.3K ﹤0.01% 3756
2022
Q1 		– Sell
-7,306
Closed -$75K – 6306
2021
Q4 		$75K Buy
+7,306
New +$108K ﹤0.01% 2436
2021
Q3 		– Sell
-1,401
Closed -$25K – 5950
2021
Q2 		$25K Sell
1,401
-11,964
-90% -$161K ﹤0.01% 3676
2021
Q1 		$159K Buy
+13,365
New +$241K ﹤0.01% 2194
2020
Q4 		– Sell
-600
Closed -$6K – 5268
2020
Q3 		$6K Sell
600
-755
-56% -$7.68K ﹤0.01% 4289
2020
Q2 		$7K Buy
+1,355
New +$6.83K ﹤0.01% 4149
2019
Q4 		– Sell
-204
Closed -$1K – 3913
2019
Q3 		$1K Buy
+204
New +$1.51K ﹤0.01% 3874

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tower Research Capital (TRC)'s INMB Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its INmune Bio (INMB) stake by 99% in Q1 2026, buying an estimated $8.35K and bringing the position to 11,772 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3752.

Tower Research Capital (TRC) first reported a position in INMB in Q3 2019 and has held it in 20 quarters since. The position peaked at $159K in Q1 2021. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Tower Research Capital (TRC) held 11,772 shares of INmune Bio worth $13.3K as of Q1 2026.
  • Tower Research Capital (TRC) bought 5,860 INmune Bio shares in Q1 2026, an estimated $8.35K.
  • INmune Bio made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3752 holding.
  • Tower Research Capital (TRC) first reported a position in INmune Bio in Q3 2019 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s INmune Bio position peaked at $159K in Q1 2021.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.